Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Shares Issued (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Shares Issued for 15 consecutive years, with $14.8 million as the latest value for Q2 2025.

  • Quarterly Shares Issued rose 338.92% to $14.8 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $18.2 million through Jun 2025, up 146.8% year-over-year, with the annual reading at $14.8 million for FY2025, 328.04% up from the prior year.
  • Shares Issued for Q2 2025 was $14.8 million at Aytu Biopharma, up from $3.4 million in the prior quarter.
  • The five-year high for Shares Issued was $14.8 million in Q2 2025, with the low at -$1.0 million in Q2 2022.
  • Average Shares Issued over 5 years is $4.9 million, with a median of $3.4 million recorded in 2024.
  • Peak annual rise in Shares Issued hit 3292.83% in 2022, while the deepest fall reached 112.74% in 2022.
  • Over 5 years, Shares Issued stood at $4.5 million in 2021, then plummeted by 74.39% to $1.2 million in 2022, then soared by 121.52% to $2.6 million in 2023, then soared by 31.92% to $3.4 million in 2024, then surged by 338.92% to $14.8 million in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at $14.8 million, $3.4 million, and $2.6 million for Q2 2025, Q2 2024, and Q2 2023 respectively.